Compare ADMA Biologics Inc (ADMA) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs SMX Security Matters plc — how do they compare? ADMA Biologics Inc trades at $9.84 (market cap $2.22B), while SMX Security Matters plc trades at $16.45 (market cap $17.04M). The key difference: ADMA Biologics Inc is far larger — about 130.3× SMX Security Matters plc's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| ADMA | SMX | |
|---|---|---|
Market Cap | $2.22B | $17.04M |
Sector | Health | Technology |
52-Week High | $20.38 | $103.71K |
52-Week Low | $7.60 | $12.87 |
Enterprise Value | $2.29B | -$14.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
SMX trades at $16.45, up 4.11% today, amid a reverse stock split effective June 1, 2026. The stock shows bearish technical signals with support at $16 and resistance at $17. Financially, the company reported a net loss of $169.18 million for 2025, with negative ROE and ROA, though it strengthened its balance sheet with $77 million in financing in 2026. Recent news highlights SMX's focus on recycled plastic verification and commercialization strategies.
The outlook remains speculative; SMX's technology addresses growing demand for material traceability, but persistent losses and high cash burn pose significant risks. Investor sentiment is cautious due to weak profitability, though institutional financing provides near-term liquidity. The stock's viability hinges on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
